The Journal of Experimental Medicine
Avanti Polar Lipids
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents
Published online 2 July 2001. doi:10.1084/jem.194.1.89
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow PPT slides of all figures
Right arrow Alert me when this article is cited
Right arrow Citation Map
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new content in the JEM
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lieberson, R.
Right arrow Articles by Glimcher, L. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lieberson, R.
Right arrow Articles by Glimcher, L. H.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
© The Rockefeller University Press, 0022-1007/2001/7/89/ $5.00
The Journal of Experimental Medicine, Volume 194, Number 1, July 2, 2001 89-98

Original Article

Tumor Necrosis Factor Receptor–associated Factor (TRAF)2 Represses the T Helper Cell Type 2 Response through Interaction with NFAT-interacting Protein (NIP45)

Rebecca Liebersona, Kerri A. Mowena, Kathryn D. McBridea, Veronica Leautauda, Xiankui Zhange, Woong-Kyung Suhd, Lin Wuc, and Laurie H. Glimchera,b
a Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, MA 02115
b Department of Medicine, Harvard Medical School, Boston, MA 02115
c Arthur D. Little, Cambridge, MA 02140
d Ontario Cancer Institute, Department of Medical Biophysiology and Immunology, Toronto, Ontario M5G 2M9, Canada
e Center for Molecular and Structural Biology, Hollings Oncology Center, Medical University of South Carolina, Charleston, SC 29425

Correspondence to: Laurie H. Glimcher, Department of Immunology and Infectious Diseases, Harvard School of Public Health, 651 Huntington Ave., Boston, MA 02115. Tel:617-432-0622 Fax:617-432-0084 E-mail:lglimche{at}hsph.harvard.edu.

Recently we have identified a novel protein NIP45 (nuclear factor of activated T cells [NFAT]-interacting protein) which substantially augments interleukin (IL)-4 gene transcription. The provision of NIP45 together with NFAT and the T helper cell type 2 (Th2)-specific transcription factor c-Maf to cells normally refractory to IL-4 production, such as B cells or Th1 clones, results in substantial IL-4 secretion to levels that approximate those produced by primary Th2 cells. In studies designed to further our understanding of NIP45 activity, we have uncovered a novel facet of IL-4 gene regulation. We present evidence that members of the tumor necrosis factor receptor–associated factor (TRAF) family of proteins, generally known to function as adapter proteins that transduce signals from the tumor necrosis factor receptor superfamily, contribute to the repression of IL-4 gene transcription and that this effect is mediated through their interaction with NIP45.

Key Words: NIP45, interleukin-4, cytokines, TRAF2, transcription


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:



  Home | Help | Feedback | Subscriptions | Archive | Search
TABLE OF CONTENTS